The J.P. Morgan Healthcare Conference in San Francisco drew over 8,000 attendees in January 2024, with a focus on science, medicine, and money. The conference showcased the potential of artificial intelligence in drug development, but some attendees were skeptical about the impact AI could have. Weight loss pills were another hot topic, as investors inquired about the market for GLP-1 agonists. Nonprofit hospitals highlighted their investment appeal, while companies discussed the development of new treatments for autoimmune diseases. Biosimilar versions of the drug Humira were also a point of discussion, as they could save the U.S. healthcare system $100 billion but face challenges in development.
Source link
What the Health Care Sector Was Selling at the J.P. Morgan Confab
